Associations between age and patient‐reported outcomes, emergency department visits, and hospitalizations among lung cancer patients receiving immune checkpoint inhibitors

Abstract

AbstractObjectiveImmune checkpoint inhibitors (ICIs) for lung cancer (LC) treatment have a more favorable safety profile and improved patient reported outcomes (PROs) compared to chemotherapy, suggesting that ICIs are advantageous for older populations. The impact of ICIs on PROs, clinical outcomes, and age in LC patients remains to be established. We examined associations between age and PROs, emergency department (ED) visits, and hospitalizations in LC patients receiving ICIs.MethodsWe performed retrospective analyses via My Wellness Check (MWC), an assessment and triage electronic medical record (EMR) integrated platform in LC patients receiving ICIs. Demographics, clinical characteristics, ED visits, and hospitalizations were extracted via EMR. Patient reported outcomes (PROMIS® anxiety, depression, fatigue, pain, physical function), and health‐related quality of life (HRQOL; FACT‐G7), were collected via MWC. We classified age into three categories (<65, 65–74, ≥75). Multiple regressions examined associations between PROs and age. Cox proportional hazards regressions assessed cumulative ED visits and hospitalizations.ResultsAmong LC patients (N = 190) receiving ICIs, patients ≥75 had lower depression (β = −5.80, p = 0.01) and higher HRQOL (β = 2.47, p = 0.05) compared with patients <65. Relative to patients <65, patients 65–74 had lower anxiety (β = −3.31, p = 0.05) and pain (β = −4.18, p = 0.03). Patients 65–74 and ≥ 75 had lower risk of an ED visit (adjusted hazards ratio [aHR] = 0.45, p = 0.05 and aHR = 0.21, p = 0.05, respectively) and patients 65–74 had lower risk of hospitalization (aHR = 0.36, p = 0.02) relative to patients <65.ConclusionsOlder LC patients (65–74; ≥75) have more favorable PROs and lower risk for negative clinical outcomes than younger (<65) patients.